IP Verse

Crystalline Forms Of An Androgen Receptor Modulator - EP3348553

The patent EP3348553 was granted to Aragon Pharmaceuticals on Jul 8, 2020. The application was originally filed on Jun 4, 2013 under application number EP18157435A. The patent is currently recorded with a legal status of "Revoked".

EP3348553

ARAGON PHARMACEUTICALS
Application Number
EP18157435A
Filing Date
Jun 4, 2013
Status
Revoked
Jul 31, 2024
Grant Date
Jul 8, 2020
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

SANDOZApr 8, 2021TER MEER STEINMEISTER & PARTNERADMISSIBLE
SCORPIOApr 8, 2021SAGITTARIUSADMISSIBLE

Patent Citations (9) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONUS20100450423-
DESCRIPTIONUS5323907
OPPOSITIONEP3812378
OPPOSITIONWO2007126765
OPPOSITIONWO2008119015
OPPOSITIONWO2013184681
SEARCHWO2007126765
SEARCHWO2008119015
SEARCHWO2011103202

Non-Patent Literature (NPL) Citations (19) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- "Impurities: Guidelines for Residual Solvents", International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH, (20051100), vol. Q3C, no. R3-
DESCRIPTION- J Clin Oncol, (19930000), vol. 11, no. 8, pages 1566 - 72-
DESCRIPTION- Nat. Med, (20040000), vol. 10, pages 33 - 39-
DESCRIPTION- Science, (20090508), vol. 324, no. 5928, pages 787 - 790-
OPPOSITION- "2.9.33 - Characterisation of crystalline solids by x-ray powder diffraction (xrpd)", Pharmeuropa, (20020100), vol. 14, no. 1, pages 185 - 191, XP003017401-
OPPOSITION- "Chapter 8 -Pharmaceutical Preformulation: the physiochemical properties of drug substances", Aulton, Pharmaceutics: The Science of Dosage Form Design, 2nd ed., (20020000), pages 113 - 138, XP055523140-
OPPOSITION- "Chapter 8 - The Importance of Solvates", Polymorphism in the Pharmaceutical Industry, (20060000), pages 211 - 233, XP055582446-
OPPOSITION- FDA Fed Register, (20000000), vol. 65, no. 251, pages 83041 - 83063, XP055553282-
OPPOSITION- GATTERMANN, DIE PRAXIS DES ORGANISCHEN CHEMIKERS, 43. Auflage, (19820000), pages 69 - 77, XP055378686-
OPPOSITION- POLYMORPHISM IN PHARMACEUTICAL SOLIDS, (19990000), page 189, 193, 236, XP055539265-
OPPOSITION- "Stability Testing of new Drug Substances and Products", ICH Guidelines 2003 Q1A (R2), (200308), XP055019637-
OPPOSITION- Stieger N., Caira, M. R.; Wessels, J. C.; Liebenberg, W., "Crystal form conversion of nevirapine solvates subjected to elevated temperature and humidity: a qualitative", Pharmazie, (20171001), vol. 72, no. 10, pages 571 - 574, XP055945741-
OPPOSITION- Schultheiss, N. ; Smit, J.P. ; Hanko, J.A., "Three isostructural solvates of finasteride and their solid-state characterization", European Journal of Pharmaceutical Sciences, Elsevier Amsterdam, NL, NL , (20091208), vol. 38, no. 5, doi:10.1016/j.ejps.2009.09.014, ISSN 0928-0987, pages 498 - 503, XP026764330
OPPOSITION- AGRIS BERZINS et al., "Structural Characterization and Rationalization of Formation, Stability, and Transformations of Benperidol Solvates", Cryst. Growth Des., (20150000), vol. 15, pages 2337 - 2351, XP055802175
OPPOSITION- OKKY DWICHANDRA PUTRA et al., "Isostructural Multicomponent Gliclazide Crystals with Improved Solubility", Cryst. Growth Des., (20160000), vol. 16, pages 6568 - 6573, XP055802178
OPPOSITION- BYRN et al., "Pharmaceutical Solids: A strategic Approach to Regulatory Considerations", Pharmaceutical Research, (19950000), vol. 12, no. 7, pages 945 - 954, XP000996386
OPPOSITION- S BYRN et al., "Pharmaceutical Solids: A Strategic Approach to Regulatory Considerations", Pharm Res, (19950000), vol. 12, no. 7, doi:10.1023/A:1016241927429, pages 945 - 954, XP055399407
OPPOSITION- CLEGG et al., "ARN-509: A Novel Antiandrogen for Prostate Cancer Treatment", Cancer Research, (20120000), vol. 72, no. 6, doi:10.1158/0008-5472.CAN-11-3948, pages 1494 - 1503, XP008166073
SEARCH- NICOLA J. GREGG, JOHN WONGVIPAT, JAMES D. JOSEPH, CHRIS TRAN, SAMEDY OUK ET AL, "ARN-509: A novel antiandrogen for prostate cancer treatment", CANCER RESEARCH, (20120120), vol. 72, no. 6, doi:10.1158/0008-5472.CAN-11-3948, pages 1494 - 1503, XP002756285 [A] 1-15 * compound ARN-509;; figure 1 *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents